Novartis AG Sponsored ADR (NVS)
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis Sales Rise Despite Generic Drug Competition in U.S.
The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC
Swiss pharmaceutical giant Novartis expects to "not really" be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at Davos. "We also have an agreement with the US government that excludes us from any tariffs we think," he said.
Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC
Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding manufacturing footprint in the country to protect it from potential tariffs.
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.
Novartis (NVS) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis: A Mispriced Hedge In A Crowded Equity Market
Novartis (NVS) offers visible earnings, stable margins, and low volatility, making it attractive amid market focus on high-growth AI plays. NVS's diversified portfolio—Oncology, Cardiovascular, Immunology, Neuroscience, and Established Medicines—balances high-margin innovation with stable, repeatable revenues. Patent cliff fears are mitigated by volume growth from new therapies and a robust pipeline across key therapeutic areas.
Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the Trump administration towards that goal following a report they are close to a pricing deal.
